VivoSim Labs, Inc. (VIVS) 10-Year Financial Performance & Capital Metrics

VIVS • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutVivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.Show more

Revenue $144K +32.1%
EBITDA -$12M +16.6%
Net Income -$2M +83.0%
EPS (Diluted) -1.70 +91.2%
Gross Margin 96.53% -3.5%
EBITDA Margin -8576.39% +36.9%
Operating Margin -8761.11% +36.7%
Net Margin -1727.78% +87.2%
ROE -35.31% +77.2%
ROIC -853.97% -48.2%
Debt/Equity 0.09 -76.8%
Interest Coverage -1261.60

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 42.0% over 5 years
✗Shares diluted 92.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-12.87%

5Y-42.01%

3Y-54.21%

TTM94.52%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM85.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM92.45%

ROCE

10Y Avg-79.25%

5Y Avg-92.61%

3Y Avg-126.55%

Latest-163.82%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	1.48M	4.23M	4.6M	3.09M	2.2M	0	1.5M	370K	109K	144K
Revenue Growth %	1.6%	1.85%	0.09%	-0.33%	-0.29%	-1%	-	-0.75%	-0.71%	0.32%
Cost of Goods Sold+	0	956K	1.03M	482K	328K	0	0	0	0	5K
COGS % of Revenue	-	0.23%	0.22%	0.16%	0.15%	-	-	-	-	0.03%
Gross Profit+	1.48M	3.27M	3.57M	2.61M	1.87M	0	1.5M	370K	109K	139K
Gross Margin %	1%	0.77%	0.78%	0.84%	0.85%	-	1%	1%	1%	0.97%
Gross Profit Growth %	1.6%	1.21%	0.09%	-0.27%	-0.28%	-1%	-	-0.75%	-0.71%	0.28%
Operating Expenses+	40.13M	41.85M	38.84M	29.88M	23.34M	16.83M	12.98M	18.1M	15.2M	12.76M
OpEx % of Revenue	27.06%	9.89%	8.44%	9.67%	10.63%	-	8.65%	48.92%	139.4%	88.58%
Selling, General & Admin	22.12M	22.3M	20.89M	14.7M	17.15M	15.71M	9.63M	9.09M	9.64M	7.69M
SG&A % of Revenue	14.91%	5.27%	4.54%	4.76%	7.81%	-	6.42%	24.56%	88.48%	53.41%
Research & Development	18.01M	19.55M	17.96M	14.75M	5.28M	1.1M	3.32M	8.88M	5.5M	5.03M
R&D % of Revenue	12.14%	4.62%	3.9%	4.77%	2.41%	-	2.21%	24.01%	50.44%	34.9%
Other Operating Expenses	0	0	0	429K	909K	15K	28K	128K	53K	39K
Operating Income+	-38.64M	-38.58M	-35.27M	-27.27M	-21.48M	-16.83M	-11.48M	-17.73M	-15.09M	-12.62M
Operating Margin %	-26.06%	-9.12%	-7.66%	-8.82%	-9.78%	-	-7.65%	-47.92%	-138.4%	-87.61%
Operating Income Growth %	-0.28%	0%	0.09%	0.23%	0.21%	0.22%	0.32%	-0.54%	0.15%	0.16%
EBITDA+	-37.83M	-37.43M	-34M	-26.29M	-20.33M	-16.79M	-11.34M	-17.44M	-14.81M	-12.35M
EBITDA Margin %	-25.51%	-8.85%	-7.39%	-8.51%	-9.26%	-	-7.56%	-47.13%	-135.83%	-85.76%
EBITDA Growth %	-0.27%	0.01%	0.09%	0.23%	0.23%	0.17%	0.32%	-0.54%	0.15%	0.17%
D&A (Non-Cash Add-back)	815K	1.15M	1.27M	980K	1.14M	41K	142K	293K	280K	266K
EBIT	-38.64M	-38.58M	-35.27M	-27.27M	-21.48M	-16.83M	-11.48M	-17.73M	-15.09M	-2.48M
Net Interest Income+	88K	198K	478K	705K	594K	15K	8K	454K	405K	130K
Interest Income	88K	198K	478K	705K	594K	15K	8K	454K	405K	140K
Interest Expense	0	0	0	0	0	0	0	0	0	10K
Other Income/Expense	71K	151K	470K	642K	2.77M	2K	33K	474K	417K	10.13M
Pretax Income+	-38.57M	-38.42M	-34.8M	-26.63M	-18.71M	-16.82M	-11.45M	-17.26M	-14.67M	-2.49M
Pretax Margin %	-26.01%	-9.08%	-7.56%	-8.62%	-8.52%	-	-7.63%	-46.64%	-134.58%	-17.26%
Income Tax+	3K	23K	2K	3K	2K	2K	2K	2K	2K	2K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-38.58M	-38.45M	-34.8M	-26.64M	-18.71M	-16.83M	-11.45M	-17.26M	-14.67M	-2.49M
Net Margin %	-26.01%	-9.09%	-7.56%	-8.62%	-8.52%	-	-7.63%	-46.65%	-134.6%	-17.28%
Net Income Growth %	-0.28%	0%	0.09%	0.23%	0.3%	0.1%	0.32%	-0.51%	0.15%	0.83%
Net Income (Continuing)	-38.58M	-38.45M	-34.8M	-26.64M	-18.71M	-16.83M	-11.45M	-17.26M	-14.67M	-2.49M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-103.20	-93.60	-76.80	-55.20	-33.60	-29.28	-15.84	-23.76	-19.25	-1.70
EPS Growth %	-0.13%	0.09%	0.18%	0.28%	0.39%	0.13%	0.46%	-0.5%	0.19%	0.91%
EPS (Basic)	-103.20	-93.60	-76.80	-55.20	-33.60	-29.28	-15.84	-23.76	-19.25	-1.70
Diluted Shares Outstanding	375.24K	407.35K	446.85K	480.75K	539.82K	575.17K	725.3K	726.09K	762.08K	1.46M
Basic Shares Outstanding	375.24K	407.35K	446.85K	480.75K	539.82K	575.17K	725.3K	726.09K	762.08K	1.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	63.65M	65.09M	46.76M	38.57M	28.32M	38.4M	29.53M	17.05M	3.94M	12.13M
Cash & Short-Term Investments	62.09M	62.75M	43.73M	36.48M	27.36M	37.36M	28.68M	16.01M	2.9M	11.31M
Cash Only	62.09M	62.75M	43.73M	36.48M	27.36M	37.36M	28.68M	15.3M	2.9M	11.31M
Short-Term Investments	0	0	0	0	0	0	0	706K	0	0
Accounts Receivable	259K	647K	1.03M	558K	111K	0	0	152K	33K	30K
Days Sales Outstanding	63.75	55.83	81.52	65.89	18.45	-	-	149.95	110.5	76.04
Inventory	334K	550K	842K	490K	0	0	0	0	297K	0
Days Inventory Outstanding	-	209.99	298.38	371.06	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	69K	4K	12K
Total Non-Current Assets+	3.92M	4.09M	3.07M	2.05M	123K	1.52M	3.76M	3.27M	2.41M	2.52M
Property, Plant & Equipment	3.71M	3.84M	2.79M	1.83M	0	381K	2.81M	2.61M	1.97M	1.29M
Fixed Asset Turnover	0.40x	1.10x	1.65x	1.69x	-	-	0.53x	0.14x	0.06x	0.11x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	213K	248K	279K	217K	123K	1.14M	948K	658K	445K	1.23M
Total Assets+	67.58M	69.18M	49.83M	40.62M	28.44M	39.92M	33.3M	20.31M	6.35M	14.65M
Asset Turnover	0.02x	0.06x	0.09x	0.08x	0.08x	-	0.05x	0.02x	0.02x	0.01x
Asset Growth %	0.26%	0.02%	-0.28%	-0.18%	-0.3%	0.4%	-0.17%	-0.39%	-0.69%	1.31%
Total Current Liabilities+	4.49M	6.01M	4.66M	3.74M	1.81M	721K	1.38M	3.67M	1.86M	3.74M
Accounts Payable	787K	1.17M	464K	628K	720K	281K	415K	331K	627K	1.64M
Days Payables Outstanding	-	447.09	164.43	475.56	801.22	-	-	-	-	120.01K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	582K	668K	525K	0	0	0	0	0	0
Other Current Liabilities	2.36M	3.48M	2.92M	2.19M	829K	378K	434K	609K	536K	998K
Current Ratio	14.18x	10.83x	10.04x	10.32x	15.65x	53.26x	21.35x	4.64x	2.12x	3.25x
Quick Ratio	14.10x	10.74x	9.86x	10.19x	15.65x	53.26x	21.35x	4.64x	1.96x	3.25x
Cash Conversion Cycle	-	-181.27	215.47	-38.61	-	-	-	-	-	-
Total Non-Current Liabilities+	905K	807K	583K	588K	0	0	1.7M	1.31M	888K	421K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	1.7M	1.31M	888K	421K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	905K	749K	564K	588K	0	0	0	0	0	0
Total Liabilities	5.39M	6.82M	5.24M	4.33M	1.81M	721K	3.09M	4.98M	2.75M	4.16M
Total Debt+	0	0	0	0	0	0	2.18M	1.8M	1.39M	942K
Net Debt	-62.09M	-62.75M	-43.73M	-36.48M	-27.36M	-37.36M	-26.49M	-13.5M	-1.51M	-10.37M
Debt / Equity	-	-	-	-	-	-	0.07x	0.12x	0.39x	0.09x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-1261.60x
Total Equity+	62.18M	62.36M	44.59M	36.3M	26.63M	39.2M	30.21M	15.33M	3.6M	10.49M
Equity Growth %	0.28%	0%	-0.29%	-0.19%	-0.27%	0.47%	-0.23%	-0.49%	-0.77%	1.91%
Book Value per Share	165.71	153.09	99.78	75.50	49.33	68.15	41.65	21.11	4.73	7.17
Total Shareholders' Equity	62.18M	62.36M	44.59M	36.3M	26.63M	39.2M	30.21M	15.33M	3.6M	10.49M
Common Stock	92K	104K	111K	124K	7K	9K	9K	9K	10K	2K
Retained Earnings	-160.87M	-199.32M	-234.12M	-260.75M	-279.46M	-296.29M	-307.74M	-325M	-339.67M	-342.16M
Treasury Stock	0	0	0	0	0	-1K	-1K	-1K	-1K	-1K
Accumulated OCI	0	-11K	0	0	0	0	0	2K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-29.37M	-29.18M	-28.86M	-20.38M	-14.88M	-13.32M	-8.45M	-12.41M	-14.65M	-9.46M
Operating CF Margin %	-19.8%	-6.9%	-6.27%	-6.59%	-6.78%	-	-5.64%	-33.54%	-134.43%	-65.7%
Operating CF Growth %	-0.5%	0.01%	0.01%	0.29%	0.27%	0.1%	0.37%	-0.47%	-0.18%	0.35%
Net Income	-38.58M	-38.45M	-34.8M	-26.64M	-18.71M	-16.83M	-11.45M	-17.26M	-14.67M	-2.49M
Depreciation & Amortization	815K	1.15M	1.27M	980K	1.14M	41K	142K	293K	280K	266K
Stock-Based Compensation	8.56M	7.39M	6.9M	5.19M	4.11M	5.56M	2.26M	2.38M	1.51M	532K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-75K	52K	21K	63K	-424K	19K	0	-125K	-154K	-8.81M
Working Capital Changes	-89K	669K	-2.25M	24K	-998K	-2.11M	597K	2.31M	-1.62M	1.04M
Change in Receivables	-259K	-388K	-381K	470K	447K	111K	0	-152K	119K	3K
Change in Inventory	-268K	-216K	-292K	352K	276K	0	0	0	-297K	-501K
Change in Payables	-600K	384K	-707K	164K	92K	-439K	134K	-148K	296K	1.02M
Cash from Investing+	-2.13M	-1.39M	-292K	-76K	747K	-393K	-409K	-966K	816K	9.03M
Capital Expenditures	-2.11M	-1.35M	-226K	-79K	0	-405K	-409K	-396K	-42K	-13K
CapEx % of Revenue	1.43%	0.32%	0.05%	0.03%	-	-	0.27%	1.07%	0.39%	0.09%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-21K	-37K	-66K	3K	747K	12K	0	0	0	9M
Cash from Financing+	43.45M	31.25M	10.11M	13.15M	4.93M	23.84M	205K	0	1.44M	8.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	320K	582K	732K	-173K	-61K	38K	-46K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-31.52M	-30.54M	-29.15M	-20.45M	-14.88M	-13.73M	-8.86M	-12.8M	-14.7M	-9.47M
FCF Margin %	-21.25%	-7.22%	-6.33%	-6.62%	-6.78%	-	-5.91%	-34.61%	-134.82%	-65.79%
FCF Growth %	-0.49%	0.03%	0.05%	0.3%	0.27%	0.08%	0.35%	-0.44%	-0.15%	0.36%
FCF per Share	-83.99	-74.97	-65.24	-42.55	-27.57	-23.87	-12.22	-17.63	-19.28	-6.47
FCF Conversion (FCF/Net Income)	0.76x	0.76x	0.83x	0.76x	0.80x	0.79x	0.74x	0.72x	1.00x	3.80x
Interest Paid	0	0	0	0	0	0	0	0	0	10K
Taxes Paid	3K	23K	2K	3K	2K	2K	2K	2K	2K	2K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-69.58%	-61.74%	-65.08%	-65.86%	-59.46%	-51.12%	-32.99%	-75.8%	-155%	-35.31%
Return on Invested Capital (ROIC)	-32202.5%	-	-11232.8%	-6007.49%	-	-2279.95%	-310.3%	-479.22%	-576.24%	-853.97%
Gross Margin	100%	77.4%	77.62%	84.41%	85.06%	-	100%	100%	100%	96.53%
Net Margin	-2601.15%	-908.91%	-756.09%	-861.7%	-852%	-	-763.2%	-4664.59%	-13459.63%	-1727.78%
Debt / Equity	-	-	-	-	-	-	0.07x	0.12x	0.39x	0.09x
Interest Coverage	-	-	-	-	-	-	-	-	-	-1261.60x
FCF Conversion	0.76x	0.76x	0.83x	0.76x	0.80x	0.79x	0.74x	0.72x	1.00x	3.80x
Revenue Growth	159.72%	185.23%	8.82%	-32.85%	-28.95%	-100%	-	-75.33%	-70.54%	32.11%

Frequently Asked Questions

Growth & Financials

VivoSim Labs, Inc. (VIVS) reported $0.1M in revenue for fiscal year 2025.

VivoSim Labs, Inc. (VIVS) grew revenue by 32.1% over the past year. This is strong growth.

VivoSim Labs, Inc. (VIVS) reported a net loss of $2.0M for fiscal year 2025.

Dividend & Returns

VivoSim Labs, Inc. (VIVS) has a return on equity (ROE) of -35.3%. Negative ROE indicates the company is unprofitable.

VivoSim Labs, Inc. (VIVS) had negative free cash flow of $10.4M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

VivoSim Labs, Inc. (VIVS) 10-Year Financial Performance & Capital Metrics

VIVS • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $144K +32.1%
EBITDA -$12M +16.6%
Net Income -$2M +83.0%
EPS (Diluted) -1.70 +91.2%
Gross Margin 96.53% -3.5%
EBITDA Margin -8576.39% +36.9%
Operating Margin -8761.11% +36.7%
Net Margin -1727.78% +87.2%
ROE -35.31% +77.2%
ROIC -853.97% -48.2%
Debt/Equity 0.09 -76.8%
Interest Coverage -1261.60

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 42.0% over 5 years
✗Shares diluted 92.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-12.87%

5Y-42.01%

3Y-54.21%

TTM94.52%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM85.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM92.45%

ROCE

10Y Avg-79.25%

5Y Avg-92.61%

3Y Avg-126.55%

Latest-163.82%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	1.48M	4.23M	4.6M	3.09M	2.2M	0	1.5M	370K	109K	144K
Revenue Growth %	1.6%	1.85%	0.09%	-0.33%	-0.29%	-1%	-	-0.75%	-0.71%	0.32%
Cost of Goods Sold+	0	956K	1.03M	482K	328K	0	0	0	0	5K
COGS % of Revenue	-	0.23%	0.22%	0.16%	0.15%	-	-	-	-	0.03%
Gross Profit+	1.48M	3.27M	3.57M	2.61M	1.87M	0	1.5M	370K	109K	139K
Gross Margin %	1%	0.77%	0.78%	0.84%	0.85%	-	1%	1%	1%	0.97%
Gross Profit Growth %	1.6%	1.21%	0.09%	-0.27%	-0.28%	-1%	-	-0.75%	-0.71%	0.28%
Operating Expenses+	40.13M	41.85M	38.84M	29.88M	23.34M	16.83M	12.98M	18.1M	15.2M	12.76M
OpEx % of Revenue	27.06%	9.89%	8.44%	9.67%	10.63%	-	8.65%	48.92%	139.4%	88.58%
Selling, General & Admin	22.12M	22.3M	20.89M	14.7M	17.15M	15.71M	9.63M	9.09M	9.64M	7.69M
SG&A % of Revenue	14.91%	5.27%	4.54%	4.76%	7.81%	-	6.42%	24.56%	88.48%	53.41%
Research & Development	18.01M	19.55M	17.96M	14.75M	5.28M	1.1M	3.32M	8.88M	5.5M	5.03M
R&D % of Revenue	12.14%	4.62%	3.9%	4.77%	2.41%	-	2.21%	24.01%	50.44%	34.9%
Other Operating Expenses	0	0	0	429K	909K	15K	28K	128K	53K	39K
Operating Income+	-38.64M	-38.58M	-35.27M	-27.27M	-21.48M	-16.83M	-11.48M	-17.73M	-15.09M	-12.62M
Operating Margin %	-26.06%	-9.12%	-7.66%	-8.82%	-9.78%	-	-7.65%	-47.92%	-138.4%	-87.61%
Operating Income Growth %	-0.28%	0%	0.09%	0.23%	0.21%	0.22%	0.32%	-0.54%	0.15%	0.16%
EBITDA+	-37.83M	-37.43M	-34M	-26.29M	-20.33M	-16.79M	-11.34M	-17.44M	-14.81M	-12.35M
EBITDA Margin %	-25.51%	-8.85%	-7.39%	-8.51%	-9.26%	-	-7.56%	-47.13%	-135.83%	-85.76%
EBITDA Growth %	-0.27%	0.01%	0.09%	0.23%	0.23%	0.17%	0.32%	-0.54%	0.15%	0.17%
D&A (Non-Cash Add-back)	815K	1.15M	1.27M	980K	1.14M	41K	142K	293K	280K	266K
EBIT	-38.64M	-38.58M	-35.27M	-27.27M	-21.48M	-16.83M	-11.48M	-17.73M	-15.09M	-2.48M
Net Interest Income+	88K	198K	478K	705K	594K	15K	8K	454K	405K	130K
Interest Income	88K	198K	478K	705K	594K	15K	8K	454K	405K	140K
Interest Expense	0	0	0	0	0	0	0	0	0	10K
Other Income/Expense	71K	151K	470K	642K	2.77M	2K	33K	474K	417K	10.13M
Pretax Income+	-38.57M	-38.42M	-34.8M	-26.63M	-18.71M	-16.82M	-11.45M	-17.26M	-14.67M	-2.49M
Pretax Margin %	-26.01%	-9.08%	-7.56%	-8.62%	-8.52%	-	-7.63%	-46.64%	-134.58%	-17.26%
Income Tax+	3K	23K	2K	3K	2K	2K	2K	2K	2K	2K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-38.58M	-38.45M	-34.8M	-26.64M	-18.71M	-16.83M	-11.45M	-17.26M	-14.67M	-2.49M
Net Margin %	-26.01%	-9.09%	-7.56%	-8.62%	-8.52%	-	-7.63%	-46.65%	-134.6%	-17.28%
Net Income Growth %	-0.28%	0%	0.09%	0.23%	0.3%	0.1%	0.32%	-0.51%	0.15%	0.83%
Net Income (Continuing)	-38.58M	-38.45M	-34.8M	-26.64M	-18.71M	-16.83M	-11.45M	-17.26M	-14.67M	-2.49M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-103.20	-93.60	-76.80	-55.20	-33.60	-29.28	-15.84	-23.76	-19.25	-1.70
EPS Growth %	-0.13%	0.09%	0.18%	0.28%	0.39%	0.13%	0.46%	-0.5%	0.19%	0.91%
EPS (Basic)	-103.20	-93.60	-76.80	-55.20	-33.60	-29.28	-15.84	-23.76	-19.25	-1.70
Diluted Shares Outstanding	375.24K	407.35K	446.85K	480.75K	539.82K	575.17K	725.3K	726.09K	762.08K	1.46M
Basic Shares Outstanding	375.24K	407.35K	446.85K	480.75K	539.82K	575.17K	725.3K	726.09K	762.08K	1.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	63.65M	65.09M	46.76M	38.57M	28.32M	38.4M	29.53M	17.05M	3.94M	12.13M
Cash & Short-Term Investments	62.09M	62.75M	43.73M	36.48M	27.36M	37.36M	28.68M	16.01M	2.9M	11.31M
Cash Only	62.09M	62.75M	43.73M	36.48M	27.36M	37.36M	28.68M	15.3M	2.9M	11.31M
Short-Term Investments	0	0	0	0	0	0	0	706K	0	0
Accounts Receivable	259K	647K	1.03M	558K	111K	0	0	152K	33K	30K
Days Sales Outstanding	63.75	55.83	81.52	65.89	18.45	-	-	149.95	110.5	76.04
Inventory	334K	550K	842K	490K	0	0	0	0	297K	0
Days Inventory Outstanding	-	209.99	298.38	371.06	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	69K	4K	12K
Total Non-Current Assets+	3.92M	4.09M	3.07M	2.05M	123K	1.52M	3.76M	3.27M	2.41M	2.52M
Property, Plant & Equipment	3.71M	3.84M	2.79M	1.83M	0	381K	2.81M	2.61M	1.97M	1.29M
Fixed Asset Turnover	0.40x	1.10x	1.65x	1.69x	-	-	0.53x	0.14x	0.06x	0.11x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	213K	248K	279K	217K	123K	1.14M	948K	658K	445K	1.23M
Total Assets+	67.58M	69.18M	49.83M	40.62M	28.44M	39.92M	33.3M	20.31M	6.35M	14.65M
Asset Turnover	0.02x	0.06x	0.09x	0.08x	0.08x	-	0.05x	0.02x	0.02x	0.01x
Asset Growth %	0.26%	0.02%	-0.28%	-0.18%	-0.3%	0.4%	-0.17%	-0.39%	-0.69%	1.31%
Total Current Liabilities+	4.49M	6.01M	4.66M	3.74M	1.81M	721K	1.38M	3.67M	1.86M	3.74M
Accounts Payable	787K	1.17M	464K	628K	720K	281K	415K	331K	627K	1.64M
Days Payables Outstanding	-	447.09	164.43	475.56	801.22	-	-	-	-	120.01K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	582K	668K	525K	0	0	0	0	0	0
Other Current Liabilities	2.36M	3.48M	2.92M	2.19M	829K	378K	434K	609K	536K	998K
Current Ratio	14.18x	10.83x	10.04x	10.32x	15.65x	53.26x	21.35x	4.64x	2.12x	3.25x
Quick Ratio	14.10x	10.74x	9.86x	10.19x	15.65x	53.26x	21.35x	4.64x	1.96x	3.25x
Cash Conversion Cycle	-	-181.27	215.47	-38.61	-	-	-	-	-	-
Total Non-Current Liabilities+	905K	807K	583K	588K	0	0	1.7M	1.31M	888K	421K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	1.7M	1.31M	888K	421K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	905K	749K	564K	588K	0	0	0	0	0	0
Total Liabilities	5.39M	6.82M	5.24M	4.33M	1.81M	721K	3.09M	4.98M	2.75M	4.16M
Total Debt+	0	0	0	0	0	0	2.18M	1.8M	1.39M	942K
Net Debt	-62.09M	-62.75M	-43.73M	-36.48M	-27.36M	-37.36M	-26.49M	-13.5M	-1.51M	-10.37M
Debt / Equity	-	-	-	-	-	-	0.07x	0.12x	0.39x	0.09x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-1261.60x
Total Equity+	62.18M	62.36M	44.59M	36.3M	26.63M	39.2M	30.21M	15.33M	3.6M	10.49M
Equity Growth %	0.28%	0%	-0.29%	-0.19%	-0.27%	0.47%	-0.23%	-0.49%	-0.77%	1.91%
Book Value per Share	165.71	153.09	99.78	75.50	49.33	68.15	41.65	21.11	4.73	7.17
Total Shareholders' Equity	62.18M	62.36M	44.59M	36.3M	26.63M	39.2M	30.21M	15.33M	3.6M	10.49M
Common Stock	92K	104K	111K	124K	7K	9K	9K	9K	10K	2K
Retained Earnings	-160.87M	-199.32M	-234.12M	-260.75M	-279.46M	-296.29M	-307.74M	-325M	-339.67M	-342.16M
Treasury Stock	0	0	0	0	0	-1K	-1K	-1K	-1K	-1K
Accumulated OCI	0	-11K	0	0	0	0	0	2K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-29.37M	-29.18M	-28.86M	-20.38M	-14.88M	-13.32M	-8.45M	-12.41M	-14.65M	-9.46M
Operating CF Margin %	-19.8%	-6.9%	-6.27%	-6.59%	-6.78%	-	-5.64%	-33.54%	-134.43%	-65.7%
Operating CF Growth %	-0.5%	0.01%	0.01%	0.29%	0.27%	0.1%	0.37%	-0.47%	-0.18%	0.35%
Net Income	-38.58M	-38.45M	-34.8M	-26.64M	-18.71M	-16.83M	-11.45M	-17.26M	-14.67M	-2.49M
Depreciation & Amortization	815K	1.15M	1.27M	980K	1.14M	41K	142K	293K	280K	266K
Stock-Based Compensation	8.56M	7.39M	6.9M	5.19M	4.11M	5.56M	2.26M	2.38M	1.51M	532K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-75K	52K	21K	63K	-424K	19K	0	-125K	-154K	-8.81M
Working Capital Changes	-89K	669K	-2.25M	24K	-998K	-2.11M	597K	2.31M	-1.62M	1.04M
Change in Receivables	-259K	-388K	-381K	470K	447K	111K	0	-152K	119K	3K
Change in Inventory	-268K	-216K	-292K	352K	276K	0	0	0	-297K	-501K
Change in Payables	-600K	384K	-707K	164K	92K	-439K	134K	-148K	296K	1.02M
Cash from Investing+	-2.13M	-1.39M	-292K	-76K	747K	-393K	-409K	-966K	816K	9.03M
Capital Expenditures	-2.11M	-1.35M	-226K	-79K	0	-405K	-409K	-396K	-42K	-13K
CapEx % of Revenue	1.43%	0.32%	0.05%	0.03%	-	-	0.27%	1.07%	0.39%	0.09%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-21K	-37K	-66K	3K	747K	12K	0	0	0	9M
Cash from Financing+	43.45M	31.25M	10.11M	13.15M	4.93M	23.84M	205K	0	1.44M	8.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	320K	582K	732K	-173K	-61K	38K	-46K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-31.52M	-30.54M	-29.15M	-20.45M	-14.88M	-13.73M	-8.86M	-12.8M	-14.7M	-9.47M
FCF Margin %	-21.25%	-7.22%	-6.33%	-6.62%	-6.78%	-	-5.91%	-34.61%	-134.82%	-65.79%
FCF Growth %	-0.49%	0.03%	0.05%	0.3%	0.27%	0.08%	0.35%	-0.44%	-0.15%	0.36%
FCF per Share	-83.99	-74.97	-65.24	-42.55	-27.57	-23.87	-12.22	-17.63	-19.28	-6.47
FCF Conversion (FCF/Net Income)	0.76x	0.76x	0.83x	0.76x	0.80x	0.79x	0.74x	0.72x	1.00x	3.80x
Interest Paid	0	0	0	0	0	0	0	0	0	10K
Taxes Paid	3K	23K	2K	3K	2K	2K	2K	2K	2K	2K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-69.58%	-61.74%	-65.08%	-65.86%	-59.46%	-51.12%	-32.99%	-75.8%	-155%	-35.31%
Return on Invested Capital (ROIC)	-32202.5%	-	-11232.8%	-6007.49%	-	-2279.95%	-310.3%	-479.22%	-576.24%	-853.97%
Gross Margin	100%	77.4%	77.62%	84.41%	85.06%	-	100%	100%	100%	96.53%
Net Margin	-2601.15%	-908.91%	-756.09%	-861.7%	-852%	-	-763.2%	-4664.59%	-13459.63%	-1727.78%
Debt / Equity	-	-	-	-	-	-	0.07x	0.12x	0.39x	0.09x
Interest Coverage	-	-	-	-	-	-	-	-	-	-1261.60x
FCF Conversion	0.76x	0.76x	0.83x	0.76x	0.80x	0.79x	0.74x	0.72x	1.00x	3.80x
Revenue Growth	159.72%	185.23%	8.82%	-32.85%	-28.95%	-100%	-	-75.33%	-70.54%	32.11%

Frequently Asked Questions

Growth & Financials

VivoSim Labs, Inc. (VIVS) reported $0.1M in revenue for fiscal year 2025.

VivoSim Labs, Inc. (VIVS) grew revenue by 32.1% over the past year. This is strong growth.

VivoSim Labs, Inc. (VIVS) reported a net loss of $2.0M for fiscal year 2025.

Dividend & Returns

VivoSim Labs, Inc. (VIVS) has a return on equity (ROE) of -35.3%. Negative ROE indicates the company is unprofitable.

VivoSim Labs, Inc. (VIVS) had negative free cash flow of $10.4M in fiscal year 2025, likely due to heavy capital investments.